news
An original medicine for the targeted treatment of ovarian and HER2-negative breast cancer is authorized in Russia
Russia’s Ministry of Health has approved Elefuza® (INN: fuzuloparib), an original medicine for the treatment of advanced epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and metastatic HER2-negative breast cancer in women with BRCA1/2 mutations. The approval of this selective poly(ADP-ribose) polymerase (PARP) inhibitor expands treatment options and access to targeted therapy for these aggressive cancers. Petrovax Pharm will supply fuzuloparib in Russia and subsequently manufacture it locally.
A unified care pathway and immune status: experts discussed new approaches to pneumonia management
An innovative drug for the immunotherapy of triple-negative breast cancer registered in Russia
Petrovax Pharm supports a documentary project about the lives of people with rare diseases
Neoadjuvant immunotherapy shifts the treatment paradigm for triple-negative breast cancer
From pregnancy preparation to vaccination: experts outline priorities in children's health at the forum "Russia and the World: Trends in Healthy Longevity"
Clinical trials of a quadrivalent meningococcal vaccine completed in Russia
Early Diagnosis and Timely Treatment: expert-defined priorities in the management of Fabry Disease presented at the “Orphan Diseases” сongress
Petrovax Pharm to launch exports of medicinal products to South Africa
